Login to Your Account

Allon Secures SPA for Tau Drug Davunetide Phase III

By Catherine Shaffer

Wednesday, January 5, 2011
Allon Therapeutics Inc. said the FDA agreed to a special protocol assessment (SPA) for its drug candidate davunetide in progressive supranuclear palsy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription